Darwin Wealth Management LLC lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 17.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 428 shares of the medical research company’s stock after selling 93 shares during the quarter. Darwin Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $227,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Raleigh Capital Management Inc. increased its position in shares of Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC increased its position in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the last quarter. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $51,000. Financial Connections Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $53,000. Finally, Operose Advisors LLC increased its position in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Insiders Place Their Bets
In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold a total of 37,711 shares of company stock worth $21,630,972 over the last quarter. Company insiders own 0.34% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Trading Up 0.7 %
NYSE:TMO traded up $4.29 during midday trading on Thursday, hitting $577.93. 1,491,192 shares of the company traded hands, compared to its average volume of 1,548,827. The firm’s fifty day moving average is $575.75 and its 200-day moving average is $535.39. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The firm has a market capitalization of $220.60 billion, a P/E ratio of 37.07, a P/E/G ratio of 2.37 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
- Five stocks we like better than Thermo Fisher Scientific
- What is a Stock Market Index and How Do You Use Them?
- Roblox: The Bottom Just Fell Out of the Metaverse
- 3 Best Fintech Stocks for a Portfolio Boost
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- ETF Screener: Uses and Step-by-Step Guide
- Uber’s Earnings Drop Is Investors Opportunity
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.